Levonorgestrel

Specifications

797-63-7CAS Number

229-433-5EC Number

(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-oneIUPAC Name

C21H28O2Chemical Formula

312.4 g/molMolecular Weight

Levonorgestrel; 797-63-7; D-Norgestrel; Mirena; Levonova; Microval; NORPLANT; Plan B; (-)-Norgestrel; D-(-)-Norgestrel; Jadelle; Microlut; d(-)-Norgestrel; Levonorgestrelum; 18-Methylnorethisterone; Norplant II; Levonelle; NorLevo; Liletta; Fallback Solo; Wy-5104; 17-Ethynyl-18-methyl-19-nortestosterone; Levosert; Microluton; Skyla; Next choice; 17alpha-Ethynyl-18-homo-19-nortestosterone; DTXSID3036496; Plan B One-Step; 18-Methyl-17-alpha-ethynyl-19-nortestosterone; Norgestrel, (-)-; Norplant System in Plastic Container; Kyleena; 13-Ethyl-17-alpha-ethynylgon-4-en-17-beta-ol-3-one; 17alpha-Ethynyl-17-hydroxy-18-methylestr-4-en-3-one; BAY86-5028; 17alpha-Ethynyl-13beta-ethyl-3-oxo-4-estren-17beta-ol; 13-Ethyl-17-alpha-ethynyl-17-beta-hydroxy-4-gonen-3-one; 5W7SIA7YZW; NSC-744007; 17-alpha-Ethinyl-13-beta-ethyl-17-beta-hydroxy-4-estren-3-one; 13-Ethyl-17alpha-ethynylgon-4-en-17beta-ol-3-one; (-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; 17-alpha-Ethynyl-13-ethyl-19-nortestosterone; CHEBI:6443; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one; DTXCID1016496; Norgeston; 13-beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(-)-; 13-Ethyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; AVIANE COMPONENT LEVONORGESTREL; LEVORA COMPONENT LEVONORGESTREL; PORTIA COMPONENT LEVONORGESTREL; TWIRLA COMPONENT LEVONORGESTREL; VIENVA COMPONENT LEVONORGESTREL; KURVELO COMPONENT LEVONORGESTREL; KYLEENA COMPONENT LEVONORGESTREL; LESSINA COMPONENT LEVONORGESTREL; MYZILRA COMPONENT LEVONORGESTREL; TRIVORA COMPONENT LEVONORGESTREL; ELIFEMME COMPONENT LEVONORGESTREL; ENPRESSE COMPONENT LEVONORGESTREL; MARLISSA COMPONENT LEVONORGESTREL; NORDETTE COMPONENT LEVONORGESTREL; ORSYTHIA COMPONENT LEVONORGESTREL; SETLAKIN COMPONENT LEVONORGESTREL; AFIRMELLE COMPONENT LEVONORGESTREL; QUARTETTE COMPONENT LEVONORGESTREL; TRIPHASIL COMPONENT LEVONORGESTREL; Postinor-2; OPCICON ONE-STEP COMPONENT LEVONORGESTREL; l Norgestrel; D Norgestrel; Norplant2; Optionelle; Afterpill; Emerres; Ezinelle; Isteranda; Jaydess; Upostelle; Aftera; AfterPlan; Curae; Julie; React; SheWise; Emerres una; Norplant System; After Banger; Athentia Next; Morning After; Stix Restart; Empowered Choice; Take Action; Her Style; Levonelle-2; Opcicon One-step; New Day; EContra One-Step; PostDay One-Step; Levonelle one step; My Choice TM; My Way; Option 2; Econ Morning After; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta(a)phenanthren-3-one; Norgestrel (-)-; Next Choice One Dose; Emergency Contraceptive; Levonorgestrel 1.5 mg; RefChem:55482; basic care levonorgestrel; Fem Choice morning after; ITHAPPENZ MORNING AFTER; Levonorgestrel Tablet, 1.5 mg; G03AC03; G03AD01; AMAZON BASIC CARE LEVONORGESTREL; LEADER Emergency Contraceptive Levonorgestrel; (1S,2R,10R,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxytetracyclo(8.7.0.02,7.011,15)heptadec-6-en-5-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16, 17-tetradecahydrocyclopenta(a) phenanthren-3-one; 212-349-8; (17alpha)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one; L-Norgestrel; norgestrel; 6533-00-2; Ovrette; Postinor; dl-Norgestrel; Follistrel; Neogest; Levonorgestrelum [INN-Latin]; Monovar; Wy-3707; Norgestrel-(-)-D; DTXSID3047477; Norgestrelum; Norgestrel (-)-form; Norplant 2; Microlution; Ovranette; Triagynon; Triciclor; MFCD00199013; Microgyn; Nordet; Trigoa; Wy 3707; Microgynon CD; Microgest ED; Logynon ED; Ovral-Lo; Levlen ED; Microgynon 21; Microgynon 28; Trinordiol 21; Trinordiol 28; MLS000069491; Minivlar 30; Monofeme 28; Neogynon 21; Nordette 21; Nordette 28; Stediril 30; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Trifeme 28; Preven; Levora-21; Levora-28; Microgynon 30 ED; Tri-Levlen 21; Rigevidon 21+7; FH 122-A; 13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; SH 850; Triquilar ED; LD norgestrel [French]; Triphasil 21; Triphasil 28; 3J8Q1747Z2; SH 70850; NCGC00159349-02; Norgestrelum [INN-Latin]; SMR000059117; Levonorgestrel implants; 13beta-Ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; E-Gen-C; Norgestrel [Progestins]; Ovoplex 30-150; (+/-)-13-Ethyl-17alpha-ethynyl-17-hydroxygon-4-en-3-one; Levogel; 13-ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one; D-(-)-Norgestrel beta-D-Glucuronide; Plan B One Step; Norplant (TN); (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one; rel-(8R,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Ovrette (TN); Mirena (TN); CCRIS 6525; CCRIS 9033; Levonorgestrel (Levonelle); HSDB 3595; HSDB 6483; LNG-IUS; (+/-)-NORGESTREL; 17alpha-Ethynyl-13-ethyl-19-nortestosterone; EINECS 212-349-8; EINECS 229-433-5; UNII-5W7SIA7YZW; BRN 2391114; FH-122A; dl-13-beta-Ethyl-17-alpha-ethynyl-19-nortestosterone; SH-850; 19-Nortestosterone, 17-ethynyl-18-methyl-; Levonorgestrel (JAN/USP/INN); Norgestrel CRS; Mirena;; UNII-3J8Q1747Z2; D -Norgestrel; Levonorgestrel RS; 1lhv; NSC-757251; 17-Ethynyl-18-methyl-19-nortestosterone Glucuronide; Levonorgestrel Glucuronide;; Levonorgestrel CRS; Oral levonorgestrel; CAS-797-63-7; LNG; SH-70850; Prestwick_109; 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-; (-)-Levonorgestrel; Levonorgestrel [USAN:USP:INN:BAN]; Levonorgestrel implant; Skyla (TN); Norgestrel [USAN:USP:INN:BAN:JAN]; BAY 86-5028; NORGESTREL [MI]; Opera_ID_552; Levonorgestrel(Levonelle); NORGESTREL [INN]; NORGESTREL [JAN]; Dexnorgestrel (obsol.);; dl-13-beta-Ethyl-17-alpha-ethynyl-17-beta-hydroxygon-4-en-3-one; Prestwick0_000773; Prestwick1_000773; Prestwick2_000773; Prestwick3_000773; Levonorgestrel (Standard); NORGESTREL [HSDB]; NORGESTREL [USAN]; Intrauterine levonorgestrel; 17-beta-Hydroxy-18-methyl-19-nor-17-alpha-pregn-4-en-20-yn-3-one; NORGESTREL [VANDF]; (+-)-13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one; (-)-Norgestrel, 98%; NORGESTREL [MART.]; CHEMBL1389; LEVONORGESTREL [INN]; LEVONORGESTREL [JAN]; NORGESTREL [USP-RS]; NORGESTREL [WHO-DD]; BIDD:PXR0194; SCHEMBL27597; BSPBio_000846; LEVONORGESTREL [HSDB]; LEVONORGESTREL [USAN]; MLS000759484; MLS001074069; MLS001423967; LEVONORGESTREL [VANDF]; SPBio_002785; LEVONORGESTREL [MART.]; BPBio1_000932; GTPL2881; Norgestrel (JP17/USP/INN); orb1305282; orb1309186; orb3139942; LEVONORGESTREL [USP-RS]; LEVONORGESTREL [WHO-DD]; LEVONORGESTREL [WHO-IP]; NORGESTREL [ORANGE BOOK]; HY-B0257R; OVRAL COMPONENT NORGESTREL; 17alpha-ethynyl-17beta-hydroxy-18a-homoestr-4-en-3-one; MSK8517; NORGESTREL [EP MONOGRAPH]; IMPLANT WITH LEVONORGESTREL; DTXCID401079284; HMS1570K08; HMS2051M08; HMS2090O06; HMS2097K08; HMS2232H06; HMS2232K12; HMS3649J10; HMS3714K08; HMS3886K18; NORGESTREL [USP MONOGRAPH]; (1S,2R,10R,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxytetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-5-one; CRYSELLE COMPONENT NORGESTREL; D-(-)-Norgestrel b-D-Glucuronide; HY-B0257; NORGESTREL (-)-FORM [MI]; LEVONORGESTREL [ORANGE BOOK]; Tox21_111593; Tox21_202872; Tox21_303623; Tox21_303658; BDBM50410522; EBC-11102; LEVONORGESTREL [EP MONOGRAPH]; LEVONORGESTREL [USP IMPURITY]; LMST02030119; MSK2222-100A; MSK8517-100A; NSC744007; s1727; s5709; ALESSE COMPONENT LEVONORGESTREL; D(-)-Norgestrel, analytical standard; LEVONORGESTREL [USP MONOGRAPH]; LYBREL COMPONENT LEVONORGESTREL; Norgestrel for system suitability CRS; PREVEN COMPONENT LEVONORGESTREL; 18,19-Dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-; AKOS015894913; LEVLITE COMPONENT LEVONORGESTREL; MSK2222-1000A; MSK8517-1000A; PLASTIC IUD WITH LEVONORGESTREL; Tox21_111593_1; CCG-100853; DB00367; FN26454; FN26455; LEVONORGESTRELUM [WHO-IP LATIN]; NC00103; NSC 744007; NSC 757251; NSC 759653; 18,19-Dinor-17-alpha-pregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (+-)-; ALTAVERA COMPONENT LEVONORGESTREL; D-(-)-Norgestrel - Bio-X trade mark; LEVONEST COMPONENT LEVONORGESTREL; QUASENSE COMPONENT LEVONORGESTREL; [18,(17.alpha.)-(-)-]; INTROVALE COMPONENT LEVONORGESTREL; NCGC00159349-03; NCGC00159349-05; NCGC00159349-14; NCGC00256735-01; NCGC00257283-01; NCGC00260418-01; SEASONALE COMPONENT LEVONORGESTREL; (1R,3aS,3bR,9aR,9bS,11aS)-11a-ethyl-1-ethynyl-1-hydroxy-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one; BN300105; SEASONIQUE COMPONENT LEVONORGESTREL; SMR000653526; CAS-6533-00-2; CLIMARA PRO COMPONENT LEVONORGESTREL; Levonorgestrel; Norgestimate EP Impurity B; Levonorgestrel for system suitability 1 CRS; Levonorgestrel for system suitability 2 CRS; LOSEASONIQUE COMPONENT LEVONORGESTREL; L1684; Levonorgestrel norgestrel D-Norgestrel Mirena; N0889; NORGESTIMATE IMPURITY B [EP IMPURITY]; NS00002177; NS00067059; T1263; Levonorgestrel 100 microg/mL in Acetonitrile; C08149; C08153; D00950; D00954; EN300-122613; Norgestrel Solution in Acetonitrile, 100ug/mL; Norgestrel Solution in Acetonitrile, 1000ug/mL; F358122; Q416950; SR-01000759218; SR-01000946725; (-)-17alpha-Ethynyl-18-methyl-19-nortestosterone; SR-01000759218-5; SR-01000946725-1; BRD-K35189033-001-03-0; BRD-K35189033-001-26-1; D-(-)-Norgestrel Solution in Acetonitrile, 100ug/mL; 13-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one; D-(-)-Norgestrel Solution in Acetonitrile, 1000ug/mL; Z1544404028; (+/-)-13-Ethyl-17a-ethynyl-17-hydroxygon-4-en-3-one; 13beta-ethyl-17alpha-ethynyl-17-hydroxy-gon-4-en-3-one; Norgestrel Working Standard (Secondary Reference Standard); 13beta-ethyl-17alpha-ethynyl-17beta-hydroxy-gon-4-en-3-one; Levonorgestrel Working Standard (Secondary Reference Standard); Levonorgestrel, British Pharmacopoeia (BP) Reference Standard; Levonorgestrel, European Pharmacopoeia (EP) Reference Standard; Levonorgestrel, United States Pharmacopeia (USP) Reference Standard; (-)-18,19-Dinor-13beta-ethyl-17beta-hydroxy-4-pregnen-20-yn-3-one; (17a)-(+/-)-13-Ethyl-17-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one; [(-)-13-ethyl-17-hydroxy-18,19-dinor-17a-pregn-4-en-20-yn-3-one; ( inverted exclamation markA)-13-Ethyl-17|A-ethynyl-17-hydroxygon-4-en-3-one; (+/-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE; (-)-13-ETHYL-17-HYDROXY-18,19-DINOR-17.ALPHA.-PREGN-4-EN-20-YN-3-ONE; 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(+/-)-; 18,19-DINORPREGN-4-EN-20-YN-3-ONE, 13-ETHYL-17-HYDROXY-, (17.ALPHA.)-(-)-; Levonorgestrel for system suitability 2, European Pharmacopoeia (EP) Reference Standard; Levonorgestrel, Pharmaceutical Secondary Standard; Certified Reference Material; (1R,3aS,3bR,9aR,9bS,11aS)-11a-Ethyl-1-ethynyl-1-hydroxy-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one; (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one (non-preferred name); rel-(1R,3aS,3bR,9aR,9bS,11aS)-11a-Ethyl-1-ethynyl-1-hydroxy-1,2,3,3a,3b,4,5,8,9,9a,9b,10,11,11a-tetradecahydro-7H-cyclopenta[a]phenanthren-7-oneSynonyms